168.85
Iqvia Holdings Inc stock is traded at $168.85, with a volume of 7.06M.
It is down -4.70% in the last 24 hours and down -29.90% over the past month.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
See More
Previous Close:
$177.18
Open:
$162.93
24h Volume:
7.06M
Relative Volume:
4.32
Market Cap:
$28.64B
Revenue:
$15.90B
Net Income/Loss:
$1.28B
P/E Ratio:
23.18
EPS:
7.2842
Net Cash Flow:
$2.21B
1W Performance:
-6.69%
1M Performance:
-29.90%
6M Performance:
-9.18%
1Y Performance:
-14.64%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
168.85 | 30.05B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
The Top 5 Analyst Questions From IQVIA's Q4 Earnings Call - Finviz
Earnings growth of 3.6% over 3 years hasn't been enough to translate into positive returns for IQVIA Holdings (NYSE:IQV) shareholders - Yahoo Finance
75,170 Shares in IQVIA Holdings Inc. $IQV Purchased by Eubel Brady & Suttman Asset Management Inc. - MarketBeat
IQVIA Holdings Inc (IQV) Shares Gap Down to $186.065 on Feb 10 - GuruFocus
Global obesity trials get boost from new IQVIA–Duke research pact - Stock Titan
Compagnie Lombard Odier SCmA Cuts Stake in IQVIA Holdings Inc. $IQV - MarketBeat
Aug EndMonth: Is IQVIA Holdings Inc stock influenced by commodity pricesTrade Performance Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
IQVIA revenue for Q4 2025 up 10.3% to USD 4,364M - Medical Buyer
Candriam S.C.A. Grows Position in IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Holdings Inc. Stock Outperforms Competitors On Strong Trading Day - Longbridge
IQVIA Expands AI Data Partnerships As Investors Weigh Growth Prospects - Yahoo Finance
Rally Mode: Is Vipshop Holdings Limited Depositary Receipt subject to activist investor interestQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
IQVIA Holdings (IQV) Valuation Check After Profit Guidance Disappoints Despite Solid Quarterly Revenue Beat - Sahm
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: IQVIA Holdings (IQV) and Molina Healthcare (MOH) - The Globe and Mail
Thrivent Financial for Lutherans Has $5.76 Million Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Envestnet Asset Management Inc. Boosts Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Fell 19% This Week. Could Shares Push Toward $260 in 2026? - TIKR.com
Jefferies lowers IQVIA stock price target to $255 on margin pressures By Investing.com - Investing.com South Africa
IQVIA Leans On AI And Boehringer Deal As Shares Struggle - Sahm
IQVIA Q4 Earnings Call Highlights - Yahoo Finance
Jefferies lowers IQVIA stock price target to $255 on margin pressures - Investing.com UK
IQV: JP Morgan Lowers Price Target While Maintaining Overweight Rating | IQV Stock News - GuruFocus
IQVIA stock price target lowered to $225 by Evercore ISI amid AI concerns By Investing.com - Investing.com Australia
UBS Adjusts IQVIA Holdings (IQV) Price Target to $240 Amidst Ste - GuruFocus
Jefferies Lowers Price Target for IQVIA Holdings (IQV) to $255 | - GuruFocus
IQV Analyst Rating Update: Stifel Lowers Price Target to $220 | IQV Stock News - GuruFocus
Barclays Analyst Lowers Price Target for IQV to $210 | IQV Stock News - GuruFocus
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term - Yahoo Finance
Leerink Partners Adjusts Price Target on IQVIA Holdings to $228 From $256, Maintains Outperform Rating - marketscreener.com
Evercore ISI Adjusts Price Target on IQVIA Holdings to $225 From $250, Maintains Outperform Rating - marketscreener.com
Barclays Adjusts IQVIA Price Target to $210 From $230, Maintains Equal Weight Rating - marketscreener.com
JPMorgan Adjusts IQVIA Price Target to $225 From $255, Maintains Overweight Rating - marketscreener.com
Citigroup Adjusts IQVIA Price Target to $200 From $230, Maintains Neutral Rating - marketscreener.com
IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis - Finviz
TD Waterhouse Canada Inc. Sells 16,903 Shares of IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Holdings Inc. (NYSE:IQV) Q4 2025 Earnings Call Transcript - Insider Monkey
Jefferies Adjusts Price Target on IQVIA Holdings to $255 From $270, Maintains Buy Rating - marketscreener.com
Stifel Adjusts Price Target on IQVIA Holdings to $220 From $273, Maintains Buy Rating - marketscreener.com
IQVIA stock price target lowered to $225 by Evercore ISI amid AI concerns - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Omnicell (OMCL) and MiMedx Group (MDXG) - The Globe and Mail
IQVIA Slipped 1% on AI Pivot: Why the Stock Could Rebound to $303 in 2026? - TIKR.com
Research Alert: CFRA Maintains Buy Rating On Shares Of Iqvia Holdings Inc. - 富途牛牛
IQVIA Q4 2025 slides: Revenue jumps 10.3%, stock falls despite beat - Investing.com Nigeria
IQVIA (IQV) Stock Trades Down, Here Is Why - Finviz
IQVIA Holdings (IQV) Q4 2025 Earnings Call Transcript - Fortune
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y - The Globe and Mail
IQVIA Holdings Inc (IQV) Q4 2025 Earnings Call Highlights: Stron - GuruFocus
IQVIA Stock Drops as 2026 Outlook Misses Wall Street Expectations - Blockonomi
IQVIA backs AI strategy as analysts question impact on business - marketscreener.com
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):